Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Public ClinicalTrials.gov record NCT02855359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.
Study identification
- NCT ID
- NCT02855359
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- denintuzumab mafodotin Drug
- rituximab Drug
- cyclophosphamide Drug
- doxorubicin Drug
- vincristine Drug
- prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2016 (Type not available)
- Primary completion
- Jan 2018 (Actual)
- Completion
- May 15, 2018 (Actual)
- Last update posted
- Mar 11, 2019
2016 – 2018
United States locations
- U.S. sites
- 34
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Saint Bernards Cancer Center | Jonesboro | Arkansas | 72401 | — |
| City of Hope | Duarte | California | 91010 | — |
| Compassionate Cancer Care Medical Group, Inc. | Fountain Valley | California | 92708 | — |
| Pacific Hematology Oncology Associates | San Francisco | California | 94115 | — |
| University of Colorado Health Memorial Hospital | Colorado Springs | Colorado | 80909 | — |
| Poudre Valley Hospital Harmony Campus | Fort Collins | Colorado | 80528 | — |
| Central Georgia Cancer Care | Macon | Georgia | 31201 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Montgomery Cancer Center | Mount Sterling | Kentucky | 40353 | — |
| Tulane University Hospital and Clinic | New Orleans | Louisiana | 70122 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Hattiesburg Clinic (Forrest General Hospital) | Hattiesburg | Mississippi | 39401 | — |
| Research Medical Center | Kansas City | Missouri | 64132 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Montefiore Medical Center - Bronx | The Bronx | New York | 10467 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Regional Medical Oncology Center | Wilson | North Carolina | 27893 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Tennessee Oncology / Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Baylor Health - Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410 | — |
| Scott and White Memorial Hospital - Temple | Temple | Texas | 76508 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Vista Oncology INC PS | Olympia | Washington | 98502 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02855359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02855359 live on ClinicalTrials.gov.